Depomed Company Profile (NASDAQ:DEPO)

About Depomed (NASDAQ:DEPO)

Depomed logoDepomed, Inc. is a specialty pharmaceutical company. The Company focuses on pain and other central nervous system (CNS) conditions. Its products include NUCYNTA ER (tapentadol extended release tablets), NUCYNTA IR (NUCYNTA) (tapentadol), Gralise (gabapentin), CAMBIA (diclofenac potassium for oral solution), Zipsor (diclofenac potassium) and Lazanda (fentanyl). Its NUCYNTA ER (tapentadol extended release tablets) is a product for the management of pain severe enough to require daily long term opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy in adults, and its NUCYNTA (tapentadol) is a product for the management of moderate to severe acute pain in adults. Its Gralise (gabapentin) is a once-daily product for the management of postherpetic neuralgia. Its CAMBIA (diclofenac potassium for oral solution) is a product for the acute treatment of migraine attacks.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Generic Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NASDAQ:DEPO
  • CUSIP: 24990810
  • Web: www.depomedinc.com
Capitalization:
  • Market Cap: $339.51 million
  • Outstanding Shares: 62,988,000
Average Prices:
  • 50 Day Moving Avg: $5.87
  • 200 Day Moving Avg: $9.04
  • 52 Week Range: $4.93 - $24.09
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.98
  • P/E Growth: 0.47
Sales & Book Value:
  • Annual Revenue: $425.34 million
  • Price / Sales: 0.80
  • Book Value: $3.36 per share
  • Price / Book: 1.60
Profitability:
  • EBITDA: $112.64 million
  • Net Margins: -26.02%
  • Return on Equity: -45.03%
  • Return on Assets: -9.34%
Debt:
  • Debt-to-Equity Ratio: 2.71%
  • Current Ratio: 0.79%
  • Quick Ratio: 0.75%
Misc:
  • Average Volume: 1.67 million shs.
  • Beta: 1.19
  • Short Ratio: 8.72
 

Frequently Asked Questions for Depomed (NASDAQ:DEPO)

What is Depomed's stock symbol?

Depomed trades on the NASDAQ under the ticker symbol "DEPO."

How were Depomed's earnings last quarter?

Depomed, Inc. (NASDAQ:DEPO) announced its earnings results on Monday, August, 7th. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of $0.09 by $0.52. The business had revenue of $100 million for the quarter, compared to the consensus estimate of $100.40 million. Depomed had a negative return on equity of 45.03% and a negative net margin of 26.02%. Depomed's revenue for the quarter was down 14.3% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.27 EPS. View Depomed's Earnings History.

When will Depomed make its next earnings announcement?

Depomed is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Depomed.

Where is Depomed's stock going? Where will Depomed's stock price be in 2017?

9 brokers have issued 1 year price targets for Depomed's stock. Their forecasts range from $5.00 to $24.00. On average, they anticipate Depomed's stock price to reach $12.67 in the next year. View Analyst Ratings for Depomed.

What are analysts saying about Depomed stock?

Here are some recent quotes from research analysts about Depomed stock:

  • 1. Cantor Fitzgerald analysts commented, "After the March 28 close, DEPO announced an agreement with Starboard that replaces CEO Jim Schoeneck as well as two incumbent board members. Guidance for 1Q17 revenue was also released, $95-100M vs. FactSet estimate." (3/29/2017)
  • 2. Janney Montgomery Scott analysts commented, "Recent developments in the 2013 patent litigation brought by DEPO against Purdue have resulted in DEPO filing an amended complaint claiming Purdue willfully violated its patents. The dispute pertains to DEPO's claim that Purdue's abuse-deterrent formulation of OxyContin, which was approved by the FDA on April 5, 2010 and subsequently commercialized, relies on inventions protected by patents for DEPO's Acuform?? drug delivery technology. With a potential royalty on cumulative net sales of $10 billion at stake, we have previously estimated, and continue to believe, a damage award of $200 million or more is possible, with little to no downside risk to DEPO in the process. We note our prior estimate did not contemplate an enhanced damage award that may result in a treble (3x) damages if DEPO prevails." (2/27/2017)

Who are some of Depomed's key competitors?

Who are Depomed's key executives?

Depomed's management team includes the folowing people:

  • James P. Fogarty CPA, Chairman of the Board
  • Arthur J. Higgins, President, Chief Executive Officer, Director
  • August J. Moretti, Chief Financial Officer, Senior Vice President
  • Matthew M. Gosling, Senior Vice President, General Counsel
  • Sharon D. Larkin, Senior Vice President - Human Resources and Administration.
  • Gerd G. Kochendoerfer, Senior Vice President, Technical Development & Quality
  • Karen A. Dawes, Independent Director
  • Louis J. Lavigne Jr., Independent Director
  • William T. McKee CPA, Independent Director
  • Gavin T. Molinelli, Independent Director

How do I buy Depomed stock?

Shares of Depomed can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Depomed's stock price today?

One share of Depomed stock can currently be purchased for approximately $5.39.


MarketBeat Community Rating for Depomed (NASDAQ DEPO)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  339 (Vote Outperform)
Underperform Votes:  227 (Vote Underperform)
Total Votes:  566
MarketBeat's community ratings are surveys of what our community members think about Depomed and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Depomed (NASDAQ:DEPO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 3 Buy Ratings
Consensus Rating:Hold (Score: 2.22)
Consensus Price Target: $12.67 (135.00% upside)
Consensus Price Target History for Depomed (NASDAQ:DEPO)
Price Target History for Depomed (NASDAQ:DEPO)
Analysts' Ratings History for Depomed (NASDAQ:DEPO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/20/2017Royal Bank Of CanadaSet Price TargetHold$10.00N/AView Rating Details
10/15/2017Piper Jaffray CompaniesSet Price TargetHold$9.00N/AView Rating Details
10/13/2017MizuhoReiterated RatingNeutral$11.00 -> $6.00N/AView Rating Details
8/8/2017Morgan StanleyDowngradeEqual Weight -> Underweight$12.00 -> $5.00HighView Rating Details
8/8/2017Janney Montgomery ScottDowngradeBuy -> Neutral$18.00 -> $8.00HighView Rating Details
5/15/2017Cantor FitzgeraldSet Price TargetHold$14.00MediumView Rating Details
3/30/2017JMP SecuritiesReiterated RatingOutperform$30.00 -> $16.00HighView Rating Details
2/18/2017Roth CapitalSet Price TargetBuy$24.00N/AView Rating Details
11/8/2016Leerink SwannSet Price TargetBuy$22.00N/AView Rating Details
3/24/2016Northland SecuritiesInitiated CoverageOutperform$22.00N/AView Rating Details
2/24/2016WallachBeth CapitalLower Price TargetBuy$33.00 -> $27.00N/AView Rating Details
(Data available from 10/22/2015 forward)

Earnings

Earnings History for Depomed (NASDAQ:DEPO)
Earnings by Quarter for Depomed (NASDAQ:DEPO)
Earnings History by Quarter for Depomed (NASDAQ DEPO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017$0.12N/AView Earnings Details
8/7/2017Q2 2017$0.09($0.43)$100.40 million$100.00 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.25)($0.43)$99.48 million$95.00 millionViewListenView Earnings Details
2/21/2017Q4 2016$0.36$0.48$123.00 million$123.90 millionViewListenView Earnings Details
11/7/2016Q3$0.35$0.28$127.22 million$111.00 millionViewListenView Earnings Details
8/3/2016Q2$0.26$0.27$118.20 million$116.70 millionViewListenView Earnings Details
5/5/2016Q1$0.17$0.12$106.88 million$104.60 millionViewListenView Earnings Details
2/22/2016Q415$0.29$0.16$110.19 million$111.20 millionViewListenView Earnings Details
11/9/2015Q3$0.19$0.33$101.64 million$105.00 millionViewListenView Earnings Details
7/29/2015Q215($0.45)$0.27$88.33 million$94.30 millionViewListenView Earnings Details
5/11/2015Q115$0.07($0.13)$33.80 million$31.70 millionViewListenView Earnings Details
2/23/2015Q414$0.07$0.21$44.66 million$33.90 millionViewListenView Earnings Details
11/5/2014Q314($0.04)($0.01)$41.50 million$51.49 millionViewListenView Earnings Details
8/6/2014Q214($0.06)($0.03)$38.03 million$67.70 millionViewListenView Earnings Details
5/8/2014Q114$0.11($0.04)$53.57 million$76.50 millionViewListenView Earnings Details
3/12/2014Q413($0.21)$0.72$19.06 million$40.60 millionViewListenView Earnings Details
11/5/2013Q313$0.07$0.11$35.55 million$37.50 millionViewListenView Earnings Details
8/7/2013Q2 2013($0.05)$0.01$29.87 million$30.00 millionViewListenView Earnings Details
5/8/2013Q1 2013($0.06)($0.10)$28.93 million$26.20 millionViewListenView Earnings Details
2/20/2013Q4 2012($0.11)($0.07)$26.48 million$26.60 millionViewListenView Earnings Details
11/5/2012Q312($0.11)($0.03)$28.06 million$33.30 millionViewN/AView Earnings Details
8/2/2012($0.22)($0.28)ViewN/AView Earnings Details
5/8/2012($0.24)($0.16)ViewN/AView Earnings Details
3/8/2012($0.31)($0.25)ViewN/AView Earnings Details
11/1/2011($0.23)($0.15)ViewN/AView Earnings Details
8/1/2011($0.05)($0.11)ViewN/AView Earnings Details
5/5/2011$1.05$1.77ViewN/AView Earnings Details
3/3/2011$0.06$0.03ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Depomed (NASDAQ:DEPO)
2017 EPS Consensus Estimate: ($0.20)
2018 EPS Consensus Estimate: $0.38
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.25)($0.20)($0.23)
Q2 20172($0.32)($0.04)($0.18)
Q3 20172($0.05)$0.04($0.01)
Q4 20172$0.05$0.38$0.22
Q1 20181$0.03$0.03$0.03
Q2 20181$0.09$0.09$0.09
Q3 20181$0.12$0.12$0.12
Q4 20181$0.14$0.14$0.14
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Depomed (NASDAQ:DEPO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Depomed (NASDAQ:DEPO)
Insider Ownership Percentage: 2.59%
Institutional Ownership Percentage: 91.25%
Insider Trades by Quarter for Depomed (NASDAQ:DEPO)
Institutional Ownership by Quarter for Depomed (NASDAQ:DEPO)
Insider Trades by Quarter for Depomed (NASDAQ:DEPO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/12/2017Arthur J HigginsInsiderBuy15,000$9.92$148,800.00View SEC Filing  
11/14/2016August J MorettiCFOSell5,000$20.84$104,200.00View SEC Filing  
9/21/2016Thadd M VargasVPSell11,250$25.00$281,250.00View SEC Filing  
8/10/2016August J. MorettiCFOSell5,000$21.40$107,000.00View SEC Filing  
8/10/2016Thadd M VargasVPSell26,290$20.92$549,986.80View SEC Filing  
5/23/2016Thadd M VargasVPSell15,000$20.00$300,000.00View SEC Filing  
5/10/2016Thadd M VargasVPSell15,000$17.64$264,600.00View SEC Filing  
5/9/2016August J MorettiCFOSell5,000$18.00$90,000.00View SEC Filing  
3/11/2016Thadd M VargasVPSell23,000$16.00$368,000.00View SEC Filing  
12/3/2015August J. MorettiCFOSell15,000$18.11$271,650.00View SEC Filing  
6/12/2015Thadd M VargasVPSell5,000$20.70$103,500.00View SEC Filing  
12/2/2014August J MorettiCFOSell5,339$15.85$84,623.15View SEC Filing  
12/2/2014James A SchoeneckCEOSell36,727$15.85$582,122.95View SEC Filing  
12/2/2014Thadd M VargasVPSell8,247$15.85$130,714.95View SEC Filing  
11/19/2014Matthew M GoslingVPSell71,000$15.36$1,090,560.00View SEC Filing  
3/14/2014James SchoeneckCEOSell17,000$14.54$247,180.00View SEC Filing  
3/14/2014Matthew GoslingVPSell21,875$14.74$322,437.50View SEC Filing  
12/2/2013Michael Md SweeneyCMOSell4,270$8.40$35,868.00View SEC Filing  
12/2/2013Thadd VargasVPSell5,296$8.40$44,486.40View SEC Filing  
5/10/2013James A SchoeneckCEOBuy25,000$5.11$127,750.00View SEC Filing  
3/6/2013Karen A DawesDirectorBuy2,000$5.96$11,920.00View SEC Filing  
8/14/2012Peter D StapleDirectorBuy5,000$5.01$25,050.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Depomed (NASDAQ:DEPO)
Latest Headlines for Depomed (NASDAQ:DEPO)
Source:
Loading headlines, please wait.

Social

Chart

Depomed (DEPO) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.